Several strategies to target HIF1A, including using HIF1A antisense oligonucleotide EZN-2968, have been investigated in preclinical models of MM and demonstrated reduced proliferation, angiogenesis and bone destruction, along with a metabolic shift to increased oxidative phosphorylation [13,14,15]. The gene discussed is HIF1A; the disease is Miyoshi myopathy.